322 related articles for article (PubMed ID: 27074574)
1. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Guillem-Llobat P; Dovizio M; Bruno A; Ricciotti E; Cufino V; Sacco A; Grande R; Alberti S; Arena V; Cirillo M; Patrono C; FitzGerald GA; Steinhilber D; Sgambato A; Patrignani P
Oncotarget; 2016 May; 7(22):32462-77. PubMed ID: 27074574
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells.
Dovizio M; Maier TJ; Alberti S; Di Francesco L; Marcantoni E; Münch G; John CM; Suess B; Sgambato A; Steinhilber D; Patrignani P
Mol Pharmacol; 2013 Jul; 84(1):25-40. PubMed ID: 23580446
[TBL] [Abstract][Full Text] [Related]
3. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Lucotti S; Cerutti C; Soyer M; Gil-Bernabé AM; Gomes AL; Allen PD; Smart S; Markelc B; Watson K; Armstrong PC; Mitchell JA; Warner TD; Ridley AJ; Muschel RJ
J Clin Invest; 2019 Mar; 129(5):1845-1862. PubMed ID: 30907747
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study.
Mikami J; Kurokawa Y; Takahashi T; Miyazaki Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2016 Jul; 19(3):817-26. PubMed ID: 26486505
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.
Boutaud O; Sosa IR; Amin T; Oram D; Adler D; Hwang HS; Crews BC; Milne G; Harris BK; Hoeksema M; Knollmann BC; Lammers PE; Marnett LJ; Massion PP; Oates JA
Cancer Prev Res (Phila); 2016 Nov; 9(11):855-865. PubMed ID: 27554763
[TBL] [Abstract][Full Text] [Related]
7. Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.
Contursi A; Sacco A; Grande R; Dovizio M; Patrignani P
Cell Mol Life Sci; 2017 Oct; 74(19):3491-3507. PubMed ID: 28488110
[TBL] [Abstract][Full Text] [Related]
8. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents.
Xu XR; Yousef GM; Ni H
Blood; 2018 Apr; 131(16):1777-1789. PubMed ID: 29519806
[TBL] [Abstract][Full Text] [Related]
9. Role of platelets in inflammation and cancer: novel therapeutic strategies.
Dovizio M; Alberti S; Guillem-Llobat P; Patrignani P
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):118-27. PubMed ID: 24118902
[TBL] [Abstract][Full Text] [Related]
10. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1.
Lichtenberger LM; Fang D; Bick RJ; Poindexter BJ; Phan T; Bergeron AL; Pradhan S; Dial EJ; Vijayan KV
Cancer Prev Res (Phila); 2017 Feb; 10(2):142-152. PubMed ID: 27998883
[TBL] [Abstract][Full Text] [Related]
11. The antiplatelet agent revacept prevents the increase of systemic thromboxane A
Alberti S; Zhang Q; D'Agostino I; Bruno A; Tacconelli S; Contursi A; Guarnieri S; Dovizio M; Falcone L; Ballerini P; Münch G; Yu Y; Patrignani P
Sci Rep; 2020 Dec; 10(1):21420. PubMed ID: 33293599
[TBL] [Abstract][Full Text] [Related]
12. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.
Mattiello T; Guerriero R; Lotti LV; Trifirò E; Felli MP; Barbarulo A; Pucci B; Gazzaniga P; Gaudio C; Frati L; Pulcinelli FM
J Am Coll Cardiol; 2011 Aug; 58(7):752-61. PubMed ID: 21816313
[TBL] [Abstract][Full Text] [Related]
13. Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice.
Sacco A; Bruno A; Contursi A; Dovizio M; Tacconelli S; Ricciotti E; Guillem-Llobat P; Salvatore T; Di Francesco L; Fullone R; Ballerini P; Arena V; Alberti S; Liu G; Gong Y; Sgambato A; Patrono C; FitzGerald GA; Yu Y; Patrignani P
J Pharmacol Exp Ther; 2019 Sep; 370(3):416-426. PubMed ID: 31248980
[TBL] [Abstract][Full Text] [Related]
14. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Cooke NM; Spillane CD; Sheils O; O'Leary J; Kenny D
BMC Cancer; 2015 Sep; 15():627. PubMed ID: 26353776
[TBL] [Abstract][Full Text] [Related]
15. Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk.
Dovizio M; Alberti S; Sacco A; Guillem-Llobat P; Schiavone S; Maier TJ; Steinhilber D; Patrignani P
Biochem Soc Trans; 2015 Aug; 43(4):707-14. PubMed ID: 26551717
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.
Rohwer N; Kühl AA; Ostermann AI; Hartung NM; Schebb NH; Zopf D; McDonald FM; Weylandt KH
Cancer Med; 2020 Apr; 9(7):2535-2550. PubMed ID: 31994315
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Volpato M; Ingram N; Perry SL; Spencer J; Race AD; Marshall C; Hutchinson JM; Nicolaou A; Loadman PM; Coletta PL; Hull MA
Cancer Chemother Pharmacol; 2021 Feb; 87(2):173-184. PubMed ID: 33040178
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenases and platelet functions.
Bruno A; Tacconelli S; Contursi A; Ballerini P; Patrignani P
Adv Pharmacol; 2023; 97():133-165. PubMed ID: 37236757
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
